Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 25, 2009 Brian Orelli	Still Enjoying Those Acquisitions, Pfizer? The drug company has inherited a lot in its acquisitions of Warner-Lambert, Pharmacia, and Wyeth. And of course, those 10,000 lawsuits.
The Motley Fool October 6, 2006 Brian Lawler	Wyeth Makes Investors Happy It's facing some challenges, but there's a lot for investors to like about this drug company.
The Motley Fool October 19, 2006 Brian Lawler	A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool April 27, 2009 Jim Mueller	Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock.
The Motley Fool June 2, 2009 Brian Orelli	Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool November 4, 2005 Rich Duprey	Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision.
The Motley Fool January 22, 2004 Alyce Lomax	Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful.
The Motley Fool May 30, 2008 Brian Orelli	For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly?
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool January 31, 2006 Stephen D. Simpson	Wyeth: Waiting on the Pipeline While Wyeth's growth today is modest, the late-stage pipeline could pay off. Investors, take note.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool August 23, 2006 S.J. Caplan	Wyeth Feeling Happy The FDA cancels a meeting related to the market application for Wyeth's experimental antidepressant. Investors, take note.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool April 10, 2006 Rich Duprey	Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
The Motley Fool May 19, 2009 Brian Orelli	The Cherry on Pfizer's Acquisition Sundae Pfizer may inherit a lawsuit.
The Motley Fool April 7, 2009 Brian Orelli	Pfizer's Mind Meld Pfizer has a plan now for its structure after its acquisition of Wyeth -- including keeping eight senior executives from its new purchase.
The Motley Fool July 20, 2005 Stephen D. Simpson	Why Not Wyeth? Wyeth has turned itself around, but is it still an attractive big-pharma investment?
The Motley Fool April 21, 2006 Stephen D. Simpson	Wily Wyeth For the most part, this business will produce high-single-digit revenue growth, and hopefully low-teens growth in earnings and cash flow. That means investors should be a little conservative buying in, but patient when holding.
The Motley Fool June 25, 2009 Brian Orelli	Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool October 15, 2009 Brian Orelli	An Ode to Wyeth Pfizer weds Wyeth today and the WYE ticker will be gone forever.
BusinessWeek September 5, 2005 Amy Barrett	The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come
The Motley Fool September 22, 2008 Brian Orelli	Ouch, That's Gotta Hurt! Acupuncture beats Wyeth's Effexor in stopping hot flashes.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
BusinessWeek June 26, 2006 Arlene Weintraub	Homegrown Hormone Therapy: How Safe? Popular alternatives to menopause drugs are under fierce attack by Wyeth and others.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool July 24, 2009 Brian Orelli	Pfizer's Bride Puts on the Makeup Pfizer may not be getting a powerhouse revenue driver in Wyeth, but at least its bride knows how to make the bottom line look pretty.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool February 2, 2010 Brian Orelli	Shaking Up the Biotech Industry A judge will decide if genes are patentable or not.
The Motley Fool July 21, 2009 Brian Orelli	Foolish Forecast: Pfizer Meanders Toward Merger Let's look at what to expect when the pharmaceutical giant releases earnings tomorrow.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool January 31, 2005 Stephen D. Simpson	Wyeth's Waiting Game The end of diet-drug litigation may be in sight, but growth hasn't recovered yet. Anyone holding or looking to buy these shares needs to understand that it will take time to get growth back on track, and there could be setbacks along the way.
Salon.com July 10, 2002 Trisha Posner	Death by hormones It's been more than 50 years since studies first sounded the alarm about hormone replacement therapy. Women, silenced by shame, have been guinea pigs of the pharmaceutical industry for too long.